The High Content Screening Market is estimated to be valued at US$ 1,847.2 Mn in 2023 and is expected to exhibit a CAGR of 5.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The High Content Screening Market provides insightful information about the product with respect to its applications in drug discovery, toxicity studies, and primary and secondary screening during drug development. High content screening helps analyze multiple parameters simultaneously which provides comprehensive data about various biological processes like cell signaling pathways, toxicity effects, and target validation during drug discovery and development.
Market Overview:
High content screening is a technique used to observe, analyze and quantify cellular responses through microscopic imaging and multi-parametric image analysis. It involves the use of automated microscopy coupled with molecular probes, image processing and analytical algorithms to quantify biological events in cells. High content screening enables analysis of multiple parameters like protein expression, phenotype, morphological changes and cell viability to gain in-depth understanding of biological pathways and impacts of drug candidates.
Market key trends:
One of the prominent trends in the high content screening market is the increasing adoption of 3D cell culture techniques. 3D cell cultures provide an environment that closely mimics in vivo condition and cellular morphology. 3D cell culture models offer improved physiological relevance and predictive power for drug testing over traditional 2D models. Their capability to better recapitulate tissue-tissue interactions and mimic 3D tissue architecture make them an attractive alternative to conventional 2D cultures. This is expected to drive increased use of 3D cell cultures in high content screening applications.
Porter’s Analysis
Threat of new entrants: The high content screening market requires large capital investments for setting up manufacturing plants and R&D facilities which limits the threat of new entrants. Bargaining power of buyers: The presence of large pharmaceutical and biotechnology companies as buyers in the market gives them higher bargaining power to negotiate on price and quality. Bargaining power of suppliers: The availability of alternative component suppliers at lower costs increases the bargaining power of suppliers in the market. Threat of new substitutes: Emerging digital pathology methods can act as substitutes but lack the high-throughput screening capabilities of high content screening currently. Competitive rivalry: Intense competition exists among the key players to develop innovative products and technologies.
SWOT Analysis
Strength: High content screening provides a multi-parametric approach for cell-based assays with high-throughput capabilities. Weakness: Requirement of skilled professionals for operation and data analysis of high content screening systems. Opportunity: Growing global pharmaceutical R&D expenditure is driving the adoption of high content screening in drug discovery. Threats: High initial investments and maintenance costs of high content screening systems pose financial challenges.
Key Takeaways
The global high content screening market is expected to witness high growth, exhibiting CAGR of 5.8% over the forecast period, due to increasing pharmaceutical R&D activities. Regionally, North America is expected to dominate the market during the forecast period due to presence of majority of key players and growing biotechnology industry in the US. The Asia Pacific region is anticipated to exhibit fastest growth rate owing to increasing investments by governments to develop healthcare infrastructure and advance biomedical research.
Key players operating in the high content screening market are Becton, Dickinson and Company, Thermo Fisher Scientific Inc., GE HealthCare, Olympus Corporation, PerkinElmer Inc., Merck Millipore Corporation, Danaher, Yokogawa Electric Corporation, Sysmex Corporation, and Thorlabs, Inc. Becton, Dickinson and Company offers high content screening technologies and services such as Acumen eX3 system for cellular analysis
HCS is used in several stages of the drug discovery process, including primary and secondary screening, target identification and validation and toxicity studies.
As HCS instruments are expensive, they add to the overall drug development expense for pharmaceutical and biopharmaceutical companies.Major Growth Drivers:The major factors that are expected to be driving the high content screening market are need for cost containment in pharma R, growth in funding for cellular research, and technological advancements in HCS solutions are expected to support the growth of the HCS market during the forecast period.
On the other hand, the high cost of HCS instruments and the dearth of knowledgeable and skilled personnel for the operation of high-content screening instruments are expected to restrain the market growth to a certain extent.Expected Revenue Growth:MarketsandMarkets forecasts the high content screening market to grow from USD 557.1 million in 2017 to USD 909.0 million by 2022, at a Compound Annual Growth Rate (CAGR) of 10.3% during the forecast period.Accessories to Fuel the Growth of high content screening market : HCS is used in several stages of the drug discovery process, including primary and secondary screening, target identification and validation and toxicity studies.
As HCS instruments are expensive, they add to the overall drug development expense for pharmaceutical and biopharmaceutical companies.HCS instruments such as flow cytometers and multimode readers have relatively complex technologies.
Experts with a good knowledge of cell-based assays and handling software & instruments are required for their optimum utilization.
A survey conducted by the Association of the British Pharmaceutical Industry (ABPI) in the U.K. revealed a lack of skilled personnel in pharmaceutical companies.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=42710391By product, the HCS instruments segment is expected to dominate the marketThe HCS instruments market accounted for the largest share of HCS market primarily attributed to advances in instrumentation and automation techniques and high prices of the HCS instruments.
HCS is used in several stages of the drug discovery process, including primary and secondary screening, target identification and validation and toxicity studies.
As HCS instruments are expensive, they add to the overall drug development expense for pharmaceutical and biopharmaceutical companiesExpected Revenue Growth:MarketsandMarkets forecasts the high content screening market to grow from USD 557.1 million in 2017 to USD 909.0 million by 2022, at a Compound Annual Growth Rate (CAGR) of 10.3% during the forecast period.Major Growth Drivers:The major factors that are expected to be driving the high content screening market are need for cost containment in pharma R, growth in funding for cellular research, and technological advancements in HCS solutions are expected to support the growth of the HCS market during the forecast period.
On the other hand, the high cost of HCS instruments and the dearth of knowledgeable and skilled personnel for the operation of high-content screening instruments are expected to restrain the market growth to a certain extent.Accessories to Fuel the Growth of high content screening market :HCS is used in several stages of the drug discovery process, including primary and secondary screening, target identification and validation and toxicity studies.
As HCS instruments are expensive, they add to the overall drug development expense for pharmaceutical and biopharmaceutical companies.HCS instruments such as flow cytometers and multimode readers have relatively complex technologies.
Experts with a good knowledge of cell-based assays and handling software & instruments are required for their optimum utilization.
A survey conducted by the Association of the British Pharmaceutical Industry (ABPI) in the U.K. revealed a lack of skilled personnel in pharmaceutical companies.Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=42710391By product, the HCS instruments segment is expected to dominate the marketThe HCS instruments market accounted for the largest share of HCS market primarily attributed to advances in instrumentation and automation techniques and high prices of the HCS instruments.
Future Market Insights (FMI), with a sharp focus on emerging regions, delivers key insights on the global High Content Screening Market in its latest report titled, “ High Content Screening (HCS) Market: Global Industry Analysis and Opportunity Assessment 2015 - 2025”.
According to the report, the global High Content Screening (HCS) market is projected to expand at a single-digit CAGR during the forecast period, accounting for US$ 382.9 Mn by 2025.
The global cell analysis instrumentation market is expected to account for US$ 2,120.5 Mn by 2025, registering a CAGR of 6.1% during the forecast period, i.e.
2015–2025.Key players in the High Content Screening (HCS) Market include Becton, Dickinson and Company (BD), Thermo Fisher Scientific Inc., GE Healthcare, Olympus Corporation, PerkinElmer Inc., Merck Millipore Corporation, Danaher Corporation (Molecular Devices), Yokogawa Electric Corporation, Sysmex Corporation and Thorlabs Inc.Demand for highly efficient screening systems, owing to increasing drug discovery initiatives among pharmaceuticals and biotechnology companies is anticipated to provide an impetus to the High Content Screening (HCS) market.
“Increasing focus of companies on penetrating untapped markets in countries in Asia Pacific and Latin America, where growth of the biotechnology and biopharmaceuticals industry in increasing, is expected to fuel demand for High Content Screening (HCS) instruments installation in the next five to six years or between 2018 and 2025,”High Content Screening (HCS) instruments are extensively used across end-use industries such as pharmaceuticals and healthcare, biotechnology companies, educational institutions, government organisations, independent contract research organisations and others.
Demand for efficient purification protocols for therapeutic cells is expected to fuel demand for high-end screening system over the next five to six years.Key SegmentBy ProductCell Imaging and Analysis EquipmentHigh Content Screening (HCS) InstrumentsHigh-End High Content Screening (HCS)Mid-End High Content Screening(HCS)Low-End High Content Screening (HCS) InstrumentsFlow CytometersConsumablesSoftwareServices By End-Use Pharmaceutical and HealthcareBiotechnology CompaniesEducational InstitutionsGovernment OrganisationsOthersBy RegionNorth AmericaLatin AmericaWestern EuropeEastern Europe Asia Pacific Excluding Japan (APEJ) Japan Middle East And AfricaFor more insights on the High Content Screening Market, you can request a sample report with TOC at http://www.futuremarketinsights.com/reports/sample/rep-gb-426Geographically, the report focusses on North America, Latin America, Eastern Europe, Western Europe, Japan, Asia Pacific Excluding Japan (APEJ), Japan and Middle East and Africa (MEA).
